CD8A and neoplasm: Mice immunized with the conjugate showed an increased vaccine response compared to those receiving the same amount of antigen admixed with MIS416 as measured by expansion of OVA-specific CD8+ T cells, and the vaccine response was associated with delayed onset of tumor growth using B16 melanoma cells in a xenograft mouse model, confirming induction of effective anti-tumor immunity [1].